Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.
If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.
By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
10
Aug 2026
A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, fight cancer cells, but is often not sufficiently activated.
10
Aug 2026
A new nationwide study finds antiviral treatment is linked to fewer intensive care unit (ICU) admissions and shorter hospital stays for children hospitalized with influenza.
10
Aug 2026
A new nationwide study finds antiviral treatment is linked to fewer intensive care unit (ICU) admissions and shorter hospital stays for children hospitalized with influenza.
10
Aug 2026
Older adults with cardiovascular disease (CVD) often have coexisting cognitive impairment and frailty, conditions that can significantly affect treatment decisions, recovery, independence and quality of life and should be considered as part of an aging-informed approach to care, according to a new American College of Cardiology Scientific Statement published in JACC, the flagship journal of the ACC.